1262133-20-9

Basic information

• Product Name: 2,6-Dichloro-4-(phenylmethoxy)pyridine
• Synonyms: 2,6-Dichloro-4-(phenylmethoxy)pyridine
• CAS NO: 1262133-20-9
• Molecular Weight: 254.116
• EINECS: -0
• Mol File: 1262133-20-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2,6-Dichloro-4-(phenylmethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-4-(phenylmethoxy)pyridine(1262133-20-9)
• EPA Substance Registry System: 2,6-Dichloro-4-(phenylmethoxy)pyridine(1262133-20-9)

Safety Data

• Hazardous Substances Data: 1262133-20-9(Hazardous Substances Data)

Usage

General Description

2,6-Dichloro-4-(phenylmethoxy)pyridine is a chemical compound with the molecular formula C12H8Cl2NO. It is a pale yellow solid with a molecular weight of 257.11 g/mol. 2,6-Dichloro-4-(phenylmethoxy)pyridine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also known for its insecticidal and fungicidal properties, making it a valuable ingredient in pest control products. Additionally, 2,6-Dichloro-4-(phenylmethoxy)pyridine has been studied for its potential applications in medicinal chemistry, particularly in the development of novel drugs targeting various diseases. Overall, this chemical plays a significant role in both the agricultural and pharmaceutical industries.

Upstream product

• 100-51-6 benzyl alcohol 
• 25194-01-8 4-nitro-2,6-dichloro-pyridine 
• 16063-69-7 2,4,6-trichloropyridine 

Downstream Products

• 1262133-21-0 tert-butyl 4-(benzyloxy)-2,6-dichloronicotinate 
• 1262133-23-2 tert-butyl 4-(benzyloxy)-2-chloro-6-phenethylnicotinate 
• 1262133-24-3 C₂₅H₂₉N₃O₃ 
• 1262133-25-4 C₂₇H₂₉N₃O₃ 
• 1262133-26-5 tert-butyl 7-(benzyloxy)-2-methyl-5-phenethyl-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylate 

Relevant articles and documents

G PROTEIN-COUPLED RECEPTOR MODULATORS AND A PHARMACEUTICAL COMPOSITION

The invention concerns a compound of formula I, a pharmaceutical formulation comprising the compound of formula I and use of the pharmaceutical composition for treating inflammatory or diabetic disease.

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

PYRIDYLPYRIDONE COMPOUNDS

The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and X are as defined in the specification.